Detection of O-glycosylated CA125 by using an electrochemical immunosensor for ovarian cancer diagnosis

Electrochemical bio- and chemosensors for cancer biomarkers: Natural (with antibodies) versus biomimicking artificial (with aptamers and molecularly imprinted polymers) recognition

Electrochemical (EC) bio- and chemosensors are highly promising for on-chip and point-of-care testing (POST) devices. They can make a breakthrough in early cancer diagnosis. Most current EC sensors for cancer biomarkers' detection and determination use natural antibodies as recognition units. However, those quickly lose their biorecognition ability upon exposure to harsh environments, comprising extreme pH, humidity, temperature, etc. So-called "plastic antibodies," including aptamers and molecularly imprinted polymers (MIPs), are hypothesized to be a smart alternative to antibodies. They have attracted the interest of the sensor research community, offering a low cost-to-performance ratio with high stability, an essential advantage toward their commercialization. Herein, we critically review recent technological advances in devising and fabricating EC bio- and chemosensors for cancer biomarkers, classifying them according to the type of recognition unit used into three categories, i.e., antibody-, aptamer-, and MIP-based EC sensors for cancer biomarkers. Each sensor fabrication strategy has been discussed, from the devising concept to cancer sensing applications, including using different innovative nanomaterials and signal transduction strategies. Moreover, employing each recognition unit in the EC sensing of cancer biomarkers has been critically compared in detail to enlighten each recognition unit's advantages, effectiveness, and limitations.

Detection of CYFRA 21-1 in human serum by an electrochemical immunosensor based on UiO-66-NH2@CMWCNTs and CS@AuNPs

In this study, an electrochemical immunosensor was constructed to detect the cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) in human serum. CYFRA 21-1 is the most sensitive tumor marker of non-small cell lung cancer (NSCLC), its content in normal human serum should be less than 3.3 ng/mL. When lung cancer cells dissolve or die, a myriad of CYFRA 21-1 is released into a tumor patient's blood circulation, and its serum content elevates strikingly. Consequently, detecting CYFRA 21-1 by an electrochemical biosensor is expected to provide a new method for the early detection and prevention of lung cancer. In this study, a composite of UiO-66-NH2 and carboxylated multi-walled carbon nanotubes (CMWCNTs) was used as the substrate material of a sensor; the resulting sensor had a large specific surface area and strong electrical conductivity. Moreover, gold nanoparticles (AuNPs) were used to bind to antibodies through an Au-S bonds. Also, a supersensitive detection of CYFRA 21-1 was achieved through the specific bindings of antigens and antibodies. Under optimal detection conditions, the change of current signal intensity of the immunosensor was proportional to the logarithm of CYFRA 21-1 concentration and had a linear relation in the range of 0.005-400 ng/mL, while the detection limit was 1.15 pg/mL (S/N = 3). The proposed immunosensor had high precision, stability, and selectivity. More importantly, the sensor was been successfully applied to detect CYFRA 21-1 in human serum with high recovery, providing a new method for early screening and dynamic monitoring of lung cancer.

Biomarkers for Early Diagnosis of Ovarian Carcinoma

The leading cause of gynecological cancer-related morbidity and mortality is ovarian cancer (OC), which is dubbed a silent killer. Currently, OC is a target of intense biomarker research, because it is often not discovered until the disease is advanced. The goal of OC research is to develop effective tests using biomarkers that can detect the disease at the earliest stages, which would eventually decrease the mortality, thereby preventing recurrence. Therefore, there is a pressing need to revisit the existing biomarkers to recognize the potential biomarkers that can lead to efficient predictors for the OC diagnosis. This Perspective covers an update on the currently available biomarkers used in the triaging of OC to gain certain insights into the potential role of these biomarkers and their estimation that are crucial to the understanding of neoplasm progression, diagnostics, and therapy.